Because SIRT7 activity strongly increased Pax5 levels in B cell progenitors, human B-ALL samples and cell lines, we propose that developing SIRT7-activating compounds to stimulate Pax5 functions may provide a basis for leukemia therapies. The gene discussed is SIRT7; the disease is precursor B-cell acute lymphoblastic leukemia.